Farxiga
- RxCUI
- 1486972
- RxNorm name
- Farxiga
- Term type
- BN
- Status
- Active
- Updated
- 2026-08-18 06:17:55
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 022014
- Active start
- 022014
- Multiple ingredient
- NO
- Branded
- YES
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| dapagliflozin | 1488564 |
Source Vocabulary Codes#
UNII Substances#
No records found.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
No records found.
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | ATC1-4 | dapagliflozin | |
| FDASPL | N0000187059 | Sodium-Glucose Cotransporter 2 Inhibitor | EPC | has_epc | dapagliflozin |
| FDASPL | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin |
| MEDRT | D001559 | Benzhydryl Compounds | CHEM | has_ingredient | dapagliflozin |
| MEDRT | D005960 | Glucosides | CHEM | has_ingredient | dapagliflozin |
| MEDRT | D003924 | Diabetes Mellitus, Type 2 | DISEASE | may_treat | dapagliflozin |
| MEDRT | D006333 | Heart Failure | DISEASE | may_treat | dapagliflozin |
| MEDRT | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin |
| MEDRT | N0000175650 | Decreased Sympathetic Activity | PE | has_pe | dapagliflozin |
| MEDRT | N0000009556 | Increased Renal Organic Ion Excretion | PE | has_pe | dapagliflozin |
| MEDRT | N0000009830 | Renal Ion Transport Alteration | PE | has_pe | dapagliflozin |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | BN_CARDINALITY | single |
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| SOURCES | Source | Multum MediSource Lexicon |